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Enhanced Thecal Androgen Production Is Prenatally
Programmed in an Ovine Model of Polycystic Ovary
Syndrome
Kirsten Hogg, Julia M. Young, Elizabeth M. Oliver, Carlos J. Souza,
Alan S. McNeilly, and W. Colin Duncan
Medical Research Council, Centre for Reproductive Health, The University of Edinburgh, The Queen’s
Medical Research Institute, Edinburgh EH16 4SA, United Kingdom
One of the hallmarks of polycystic ovary syndrome (PCOS) is increased ovarian androgen secretion
that contributes to the ovarian, hormonal, and metabolic features of this condition. Thecal cells
fromwomenwithPCOShaveanenhanced capacity for androgen synthesis. To investigatewhether
this propensity is a potential cause, rather than a consequence, of PCOS,weused anovine prenatal
androgenizationmodelofPCOSandassessedewesat11monthsofage.PregnantScottishGreyface
eweswere administered 100mg testosteronepropionate (TP) or vehicle control twiceweekly from
d 62 to 102 of gestation, and female offspring (TP  9, control  5) were studied. Prenatal TP
exposure did not alter ovarian morphology or cyclicity, or plasma androgen, estrogen, and go-
nadotropin concentrations, at this stage. However, follicle function was reprogrammed in vivo
with increasedproportionsof estrogenic follicles (P0.05) in theTP-exposed cohort. Furthermore,
in vitro the thecal cells of follicles (4 mm) secreted more LH-stimulated androstenedione after
prenatal androgenization (P0.05), associatedwith increasedbasal expressionof thecal StAR (P
0.01), CYP11A (P 0.05),HSD3B1 (P 0.01), CYP17 (P 0.05), and LHR (P 0.05). This provides the
first evidence of increased thecal androgenic capacity in the absence of a PCOS phenotype, sug-
gesting a thecal defect induced during fetal life. (Endocrinology 153: 450–461, 2012)
Polycystic ovary syndrome (PCOS) is themost commonendocrine disorder in young women (1). Increased
ovarian androgen production is a PCOS trait that is man-
ifest clinically and contributes to the metabolic dysfunc-
tion and ovarian phenotype (1–3). According to the 2003
Rotterdam consensus, the criteria for the diagnosis of
PCOS include the presence of hyperandrogenemia, a poly-
cystic ovary morphology on ultrasound, and chronic an-
ovulation (4). Polycystic ovaries are characterizedbyapoly-
follicular phenotype, inwhich there is increased recruitment
to, or persistence of, small antral-stage follicles (5) and there
is an associated increased secretion of LH that contributes to
enhanced ovarian androgen production (3).
The etiology of PCOS is not understood and although
there are features of heritability (6), a robust genotype has
not been identified (7). There is increasing evidence that
the adult PCOS phenotype is programmed in fetal life (8,
9). Exposure of a female fetus to increased androgen con-
centrations in utero results inovarian, hormonal, andmet-
abolic characteristics of PCOS in the adult (8, 10). Since
features of PCOS occur in congenital virilizing disorders
(11), it is likely that this experimental paradigm can in-
form us about the molecular mechanisms involved in the
development of PCOS in women. This PCOS-like model
has been developed in a number of species including the
sheep (10, 12).
Evidence suggests that theca cells from women with
PCOS function differently. Thecal cell androstenedione is
increased in women with PCOS (3), which is augmented
by increased expression of thecal LH receptor (LHR) (13)
and intrinsic alterations in thecal steroidogenic gene ex-
pression (13, 14). Global enhancement of the steroido-
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genic pathway is found in thecal cells of PCOS women,
with up-regulation of StAR (13), CYP11A, and CYP17
(13, 14) and increased enzyme activity of 17-hydroxy-
lase, 3-hydroxysteroid dehydrogenase (HSD), and 17-
HSD (14). Because hyperandrogenemia is a key etiological
agent for many of the clinical features of PCOS, this is a
key finding. However, these observations are present in
thecal cells from women already manifesting the ovarian,
hormonal, andmetabolic features of PCOS. It is therefore
not knownwhether enhanced thecal androgenproduction
is a cause or consequence of PCOS. Thecal cells are re-
cruited from stromal tissue surrounding follicles (15),
which express androgen receptors and thus could be
primed in fetal life during ovarian development. Alterna-
tively, enhanced thecal androgen production could be
manifest only in adult life as a result of the associated
alterations in the metabolic and gonadotropin environ-
ment in women with PCOS.
In an ovine model of PCOS, maternal exposure to tes-
tosterone propionate (TP) from d 30 to d 90 of a 147 d
gestation results in ovarian, hormonal, andmetabolic fea-
tures of PCOS (16–19), and ovarian cyclicity is absent by
the second breeding season (20). There is also masculin-
ization of the external genitalia (21, 22). This is avoided
when TP exposure is commenced at d 60, although the
PCOS-like features are more subtle (23, 24). We hypoth-
esized that young adult ewes exposed to TP during midg-
estation would be predisposed to PCOS-like features that
are not yet clinically manifest. This would allow assess-
ment of the thecal cell with a reduced number of con-
founding factors.
The objective of this study was to characterize ewes at
11months of agewhosemothers had been treatedwithTP
from d 62 to d 102 of gestation and compare these with
control animals. We assessed the following: 1) ovarian
morphology, the number of different classes of follicles,
and follicular dynamics; 2) systemic hormone profiles and
ovarian function; 3) thecal cell androgen production from
individual follicles in vivo and in vitro in the presence or
absence of exogenous LH; and 4) basal thecal cell expres-
sion of genes important for steroidogenesis and growth
and development.
The results show that thecal cells from folliclesmatched
in size and developmental stage in TP fetal-exposed ewes
with normal endocrine and metabolic profiles have in-
creased androgen synthesis, indicating that enhanced the-
cal androgen production is preprogrammed in fetal life.
Materials and Methods
Reagents
All reagents and chemicals were obtained from Sigma-
Aldrich (Poole, UK) unless otherwise stated.
Animal treatment and collection of tissue
All experiments were conducted under a UK Home Office
project license after local ethical committee approval. Scottish
Greyface ewes andTexel ramsweremated and pregnancieswere
evenly and randomly divided between control and treatment
groups. Pregnant ewes were administered 100 mg TP [1 ml im;
AMS Biotechnology (Europe) Ltd., Abingdon, UK], in vegetable
oil, twice weekly from d 62 to d 102 of a 147 d gestation. Con-
trols (C; 1 ml im) were treated with vehicle only. The resulting
females (TP9,C5)were killed at the endof the first breeding
season (March) at 11 months of age. Before the animals were
killed, estrous cycles were synchronized by the administration of
125 mg prostaglandin estrumate (im; Schering Plough Animal
Health,WelwynGardenCity,UK) twice, 11dapart, andanimals
were killed approximately 24 h after the second prostaglandin
injection to ensure theywere in the follicular phase. Both ovaries
were immediately collected and weighed. One ovary was pro-
cessed for histological assessment, whereas the other was imme-
diately dissected for tissue culture and gene expression studies.
Histology and stereological assessment of ovarian
sections
One ovary from each animal was fixed in Bouins solution for
24 h and transferred to 70% ethanol before embedding in par-
affin wax. The ovaries were serial sectioned (5 m), and every
20th sectionwas stainedwith hematoxylin and eosin (H&E).All
primordial, primary, preantral, and antral follicles were counted
in at least eight sections from every ovary. Follicles were cate-
gorized into developmental stage according to standard classi-
fications (25, 26). Counting was performed blindly and the av-
erage number of follicles per section for each developmental
stage classification was calculated for each animal and these val-
ues used for statistical analysis.
Immunohistochemistry and immunohistochemical
assessment
Tissue sections (5m)wereprocessed for immunohistochem-
istry as previously described (27). Primary antibodies used were
Ki67 (1:200; mouse monoclonal, NCL-Ki67-MMI; Novocastra
Laboratories, Newcastle, UK) and cleaved caspase-3 (1:100;
rabbit polyclonal, Asp175 no. 9961; Cell Signaling Technology
Inc., Danvers, MA). The same method for follicle counting was
used to count the number of antral follicles that were immuno-
positive for Ki67 and cleaved caspase-3. The average number of
immunopositive and immunonegative follicles per section was
calculated for each animal, and this value used in the propor-
tional analysis.
Collection of follicular fluid and thecal cell culture
Oneovary fromeachanimalwasplaced inadishcontainingPBS
and cut in half. Individual antral follicles were carefully dissected
using scissors and fine forceps under a dissecting microscope and
cleaned as described previously (28). The diameter (millimeters) of
each individual follicle was recorded. Each follicle was transferred
to an individual well containing 1 ml PBS in a 24-well plate, the
follicle was cut in half to release the follicular fluid, and the gran-
ulosa cells were scraped out. The thecal shell was removed and the
PBS containing follicular fluid andgranulosa cellswas separatedby
centrifugationat400g for10minat roomtemperature.The fluid
was collected and stored at20 C.
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The thecal shell was peeled from the inside of the follicle shell
and cut into two similar-size pieces.Halfwas immediately placed
in 250 l RNAlater (Applied Biosystems, Carlsbad, CA) and
stored at20 C, whereas the other half was cultured in 24-well
plates, initially in 1ml medium 199 for 1 h, and then transferred
to media containing 100 ng/ml LH (ovine LH R-23; National
Institute of Diabetes and Digestive and Kidney Diseases,
Bethesda, MD) and cultured for 2 h at 37 C and 5% CO2. This
concentration has been shown to maximally stimulate theca cell
function (29). After the culture period,mediawas stored at20C.
Follicular and media hormonal measurements
Well-established and reported specific in-house assays were
used to measure sex steroids by direct assay of serum extracts
(30). Assay specificity was indicated by low cross-reactivity of
known steroids that are structurally related. A RIA for andro-
stenedione was performed in the follicular fluid and the culture
media collected from the thecal cell cultures as described previ-
ously (29, 30). Briefly, a rabbit antiandrostenedione (1:320,000;
07-109216; MP Biomedicals, Illkirch, France) and a 125I-radio-
labeled androstenedione tracer (MP Biochemicals) were used
with a donkey antirabbit secondary antibody (1:60; T022; Di-
agnostics Scotland, Edinburgh, UK) in normal rabbit serum (1:
600; MP Biomedicals). The intra- and interassay coefficients of
variation (CV) were 4 and 7.5%, respectively, and assay sensi-
tivity was 10 pg/ml. For androstenedione measurements in me-
dia, concentrations were expressed as picograms per milliliter
and in follicular fluid as nanograms per follicle after conversion
based on initial dilution and follicle diameter.
Anin-houseELISAwasusedtomeasureestradiolinovinefollicular
fluid.Ninety-sixmicrowell plateswereprecoatedwithdonkeyantish-
eep IgG (1:200; 713-005-147; Jackson ImmunoResearch, Newmar-
ket, UK) and stored overnight at 4 C in a humidity chamber. On
d 2, coating buffer was discarded and the plate washed thor-
oughly with wash buffer (deionized water  0.1% Tween 20).
Estradiol antibody (in-house; ASMR32) was added to each well
and incubated for 3 h at room temperature. The liquid was dis-
cardedand theplatewashed repeatedly.Thedilutionof follicular
fluid ranged from 1:2 to 1:100. In-house estradiol tracer conju-
gated to horse radish peroxidase was incubated with the sample
for 2 h at room temperature, followed by washing steps. Sub-
strate consisting of 0.1 M citrate phosphate buffer (pH 5.0),
0.03% (vol/vol) hydrogen peroxide and 0.1% (wt/vol) o-phe-
nylenediame dihydrochloride was added to each well. The plate
was incubated for 30minat roomtemperature in thedarkandthe
reaction stopped with the addition of concentrated sulfuric acid
diluted 1:10 in deionized water, and spectrophotometry was per-
formedat495nm.The intra- and interassayCVwere6.7and10%,
respectively,andassaysensitivitywas30pg/ml.Estradiolvalues less
than ()30 ng/folliclewere regarded as lowand those follicleswere
classed as nonestrogenic. Estrogenic follicles were determined by
values of, or greater than ()30 ng/follicle.
Follicular phase hormonal measurements
Progesterone was measured by RIA weekly over a 5-wk pe-
riod from approximately 9months of age, during the first breed-
ing season, to determine ovulation frequency. The primary an-
tibody used was rabbit anti-11-hydroxyprogesterone (1:6000;
PROG-no. 51C; Pantex, Santa Monica, CA). The intra- and in-
terassay CV were 8 and 10%, respectively, and assay sensitivity
was 400 pg/ml. Progesterone values greater than ()1 ng/ml
were considered representative of ovine luteal concentrations
and therefore indicative of an ovulation (31, 32).
Thereafter estrous cycles were synchronized as described
above, and serial blood samplingwas conducted for a 6-h period
commencing at 1000 h, on d 2 of the estrous cycle, and LH
concentration was measured at 10-min intervals using an in-
house LH RIA, as previously described (28, 33), using reagents
supplied by the National Institute of Diabetes and Digestive and
Kidney Diseases (ovine LHR-23) and a specific rabbit antiovine
LH antiserum ASMR29 (28). The average value over all time
points (37 in total) was calculated to give an overall represen-
tation of LH concentration. Peaks were defined if the LH con-
centration was 1 ng/ml and were approximately one third
greater or more of that of the two preceding LH values, in line
with previously published studies in the sheep (34). FSH con-
centration was similarly measured by in-house RIA (35) in sam-
ples collected at the beginning and end of serial sampling to give
a representative FSH profile. Corresponding LH values at these
time points (1000 and 1600 h) were used to calculate the LH to
FSH ratio. The intra- and interassay CV for LH and FSH assays
were 10% and assay sensitivity was 200 pg/ml and 1 ng/ml,
respectively.
Steroid hormone measurements were also conducted. Andro-
stenedionewasmeasured byRIA as described above and treated in
the sameway as the culturemedia samples. Testosteronewasmea-
sured by RIA, for which the primary antibody used was rabbit
antitestosterone(1:600,000;R3S07-259;AMSBiotechnology,Ox-
fordshire, UK). The intra- and interassay CV were 4 and 8%, re-
spectively, and assay sensitivity was 15 pg/ml. Peripheral estradiol
concentrationsweremeasured using theMAIA estradiol ELISAkit
(37001; InvernessMedical UK, Cheshire, UK) as per the manufac-
turer’s instructions, in which the intra- and interassay CV were 6
and 9%, respectively, and assay sensitivity was 0.3 pg/ml.
Quantitative real-time PCR (qRT-PCR)
mRNAwas extracted from the thecal cells stored inRNAlater
(AppliedBiosystems) using theRNeasymicrokit (QIAGENLtd.,
Crawley, UK)withRNeasyMiniElute spin columns (QIAGEN),
according to the manufacturer’s instructions, and stored at80
C. Good-quality mRNA was obtained from individual follicles
that were 3 mm or greater in diameter, and thecal gene expres-
sionwas analyzed.RNAconcentration andpuritywasmeasured
using a NanoDrop 1000 spectrophotometer (Fisher Scientific
Ltd., Loughborough, UK), and cDNAwas synthesized from100
ng RNA using the SuperScript VILO cDNA synthesis kit (Invit-
rogen, Paisley, UK) and stored at 20 C.
Primers were designed for qRT-PCR (Table 1) using Primer3
Input version 0.4 software (Primer 3, Rozen S. and H. J. Ska-
letsky; http://frodo.wi.mit.edu/primer3/) and products validated
by DNA sequencing. SYBR Green qRT-PCR was carried out as
previously described (36), using reagents from Applied Biosys-
tems. Gene expression was analyzed relative to internal house-
keeping gene GAPDH and was quantified using the CT
method.
Statistical analyses
Values that were P  0.05 were considered statistically sig-
nificant. For the analysis of follicle number, hormonal assess-
ment and qRT-PCR gene expression experiments, in which the
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differences between themean values fromCandTP cohortswere
compared, a Student’s unpaired t test assuming equal variances
was used. In the instances in which data were not normally dis-
tributed, a Mann-Whitney nonparametric test was alternatively
used. An ANOVA followed by post hoc analysis (Bonferroni’s
multiple comparison test) was used to detect alterations in an-
drostenedione secretion over increasing follicle size. A paired t
test was performed to assess the effect of thecal cell LH response
within treatment groups. Values are presented as mean  SEM.
Proportional assessment of follicle growth and atresia dynamics
and estrogenic statuswere subjected to a 2 test. These values are
presented as a percentage.
Results
The effect of prenatal androgenization on ovarian
morphology in adolescent sheep
There was no difference in the average ovarian weight
between control animals (0.83  0.08 g) and those ex-
posed to increased prenatal androgens (1.090.09 g;P
0.05), and overall body weights of animals at the time the
animals were killed were not different (C, 45.2  3.7 vs.
TP, 46.8  2.2 kg). Histological examination of H&E-
stained ovarian sections did not reveal clear organiza-
tional differences between ovaries from control or TP-
exposed offspring (Fig. 1A). Stereological assessment of
follicle number and stage of development showed no dif-
ferences in the numbers of primordial (Fig. 1B), primary,
preantral, or antral follicles (Fig. 1C) as a result of prenatal
androgenization. Whole ovarian follicular dissection also
showed no differences in the numbers of antral follicles
(2 mm) per ovary between control and prenatally TP-
exposed ewes (Fig. 1D). Immunohistochemical analysis of
antral follicle cell proliferation and cell death was con-
ducted using markers for the activated cell cycle (Ki67)
and cell apoptosis (cleaved caspase-3). Prenatal androg-
enization was not associated with increased proliferating
follicles (Fig. 1E); however, it did result in a small increase
in follicle cell death (P  0.05; Fig. 1F). Follicle fluid es-
tradiol concentrations were also measured as an indica-
tion of follicle health. Assessment of the control cohort
showed maturational differences in estradiol synthesis in
follicles3 mm and3 mm diameter sizes (5.7 1.7 vs.
27.0 11.4 ng/follicle, respectively; P 0.053). Ovaries
from the prenatally androgenized cohort contained 25%
more3mmestrogenic follicles (P0.05) and50%more
3 mm estrogenic follicles (P 0.05) than controls (Fig.
1G). These results indicate a clear shift in the proportion
of healthy and potentially persisting follicles in the pre-
natally androgenized cohort in comparisonwith controls.
The effect of prenatal androgenization on the
hypothalamic pituitary ovarian axis
Representative profiles from the 6-h serial sampling of
plasma LH concentrations are shown in Fig. 2A. Prenatal
androgenization had no effect on pulse frequency (Fig.
2B), average LH concentrations (Fig. 2C), FSH concen-
trations (Fig. 2D), and therefore the LH to FSH ratio (C,
0.69  014 vs. TP, 0.65  0.17). In adolescent ewes,
midgestationTPexposuredidnot alter ovarian cyclicity as
assessed by progesterone measurement (Fig. 2E). In addi-
tion, therewasnodifference in systemic estradiol (Fig. 2F),
androstenedione (Fig. 2G), or testosterone (Fig. 2H) con-
centrations in the control and prenatally TP-exposed
cohorts. Therefore, in young adult ewes, midgestation an-
drogenization did not appear to effect peripheral endo-
crine parameters by the first breeding season.
The effect of prenatal androgenization on thecal
androstenedione biosynthesis
Androstenedione concentrations were measured in
vivo in the follicular fluid of individual follicles. Analysis
TABLE 1. List of gene names and corresponding accession numbers for which forward and reverse primers were
designed and PCR amplicon size
Gene (accession no.) Forward sequence Reverse sequence Product size (bp)
StAR (NM_001009243) GCATCCTCAAAGACCAGGAG CTTGACACTGGGGTTCCACT 194
CYP11A (NM_001093789.1) CAACGTCCCTCCAGAACTGT CAGGAGGCAGTAGAGGATGC 172
HSD3B1 (NM_001135932) GGAGACATTCTGGATGAGCAG TCTATGGTGCTGGTGTGGA 200
CYP17 (NM_001009483) AGACATATTCCCTGCGCTGA GCAGCTTTGAATCCTGCTCT 215
LHR (NM_214449.1) TCCGAAAGCTTCCAGATGTT GAAATCAGCGTTGTCCCATT 199
AR (XM_001253942) GCCCATCTTTCTGAATGTCC CAAACACCATAAGCCCCATC 233
ER (NM_001009737.1) GAGGCCTCCATGATGATGTC GGTCTGGAGCAAAGATGAGC 208
INHA (NM_174094) GAGCCCGAGGACCAAGATGTCTCC CCTCAGCCTCTCCAGCATCTGGC 91
INHBA (NM_174363) GAAGAGACCCGATGTCACCCAGC TGTCGTCCTCTATCTCCACGTACCCG 113
INHBB (NM_176852) ATGGCCTGGCCTCCTCCCG CTTCAGGTAGAGCCACAGGCTGGC 101
INSR (XM_002688832.1) CACCATCACTCAGGGGAAAC CAGGAGGTCTCGGAAGTCAG 247
IGF1R (XM_002696504.1) CCAAAACCGAAGCTGAGAAG TCCGGGTCTGTGATGTTGTA 199
GAPDH (NM_001034034) GGCGTGAACCACGAGAAGTATAA AAGCAGGGATGATGTTCTGG 229
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was divided into follicle sizes of3mm, 3–4mm, and4
mm in diameter because there were maturational changes
in androstenedione concentrations between these stages.
Follicular fluid androstenedione concentrationsdecreased
with increasing follicle size in control animals (overall
ANOVA comparing3 mm, 3–4 mm, and4 mm sizes;
P 0.001). In the TP-treated cohort, this finding was not
observed due to a 5-fold increase (P 0.055) in follicular
fluid androstenedione concentrations in follicles 4 mm
compared with control follicles of this size (Fig. 3A).
In vitro, the small nonsignificant increase in basal and
LH-stimulated thecal androstenedione secretion with fol-
licle size in control animals was significant in the prena-
tally androgenized cohort (overallANOVAP0.001and
Bonferroni post hoc analysis for 3 mm vs. 3–4 mm
groups, P 0.01; Fig. 3B). The thecal cells of follicles3
mm responded to the addition of LHwith either a trend or
significant increase in androstenedione secretion in both
the control and TP-treated groups (3–4 mm, C, P 0.05
and TP, P 0.01, and4 mm, TP, P 0.05; Fig. 3C). In
FIG. 1. A, Representative tiled images of H&E-stained ovarian sections from prenatally C (n  5) and TP -exposed (n  9) adolescent ewes. Scale
bars, 1 mm. Stereological quantification of primordial follicle number (B) and activated follicles (C), including primary, preantral, and antral follicles,
was performed in the ovary processed for histology. D, Antral follicles were dissected from the opposite ovary and the number of follicles 2 mm
was recorded. Data in B–D are presented as the mean  SEM and were analyzed using an unpaired t test. The proportion of proliferating (E) and
atretic (F) antral follicles was quantified by reference to follicle immunostaining with Ki67 and cleaved caspase-3, respectively. G, The proportion of
estrogenic follicles (follicular fluid estradiol 30 ng/follicle) from C and TP ovaries were determined. Data in E, F, and G are percentages and were
analyzed using a 2 test where *, P  0.05.
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follicles 4 mm, post-LH thecal androstenedione secre-
tion was increased in the prenatal TP-exposed group (P
0.05; Fig. 3D). Indeed, androstenedione secretion from
control LH-stimulated thecal cells from follicles 4 mm
was similar to the unstimulated thecal cell output from
follicles 4 mm in TP-exposed animals (Fig. 3D). Basal
thecal androstenedione secretion also tended to be in-
creased in follicles4 mm in the TP-treated group; how-
ever, this did not reach significance (P 0.095; Fig. 3D).
Thecal androstenedione output was not altered in TP-ex-
posed animals in 3-4 mm follicles; however, paradoxi-
cally, there was decreased secretion in the follicles3mm
in both the absence (P 0.05) and presence (P 0.05) of
LH (Fig. 3D); however, this finding was not mirrored in
vivo. Nevertheless, clear enhancement of androgen secre-
tionwas observed in the largest antral follicles both in vivo
and in vitro in the young, prenatally androgenized ewe.
The effect of prenatal androgenization of thecal
cell gene expression
In the theca cells of follicles 3 mm, there was an up-
regulation in the expression of steroidogenic acute regu-
FIG. 2. A, Representative LH profiles from a C and TP individual in which LH concentrations are plotted as single values. B, The average number of
LH pulses occurring over the sampling period in C and TP cohorts. Peripheral concentrations of LH (C) and FSH (D) were measured and treatment
groups were analyzed using an unpaired t test. Values are mean  SEM. E, The proportion of animals that were ovulating by measurements of
luteal progesterone over a 5-wk period from 9 months of age. Values are percentages and data were analyzed using a 2 test. Peripheral
concentrations of estradiol (F), androstenedione (G), and testosterone (H) were measured and treatment groups were analyzed using an unpaired t
test. Values are mean  SEM.
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latory (StAR) gene in prenatally androgenized offspring
(P 0.01; Fig. 4A). Gene expression was also assessed in
the same cohorts with follicle groups split into non-estro-
gen-producing andhealthy estrogen-producing follicles to
ensure that gene expression changes were not a conse-
quence of a higher number of estrogenic follicles in the TP
cohort. A trend for increased StAR expressionwas present
in nonestrogenic follicles (P 0.11) and was significantly
up-regulated in healthy estrogenic follicles (P 0.05; Fig.
4A). There was also an up-regulation in thecal CYP11A
gene expression in these follicles (P0.05; Fig. 4B),which
occurredpredominantly in thenonestrogenic follicles (P
0.05; Fig. 4B). Prenatal androgenswere also found to pro-
gramthecal cell expressionofHSD3B1 (P0.01),CYP17
(P 0.05), andLHR (P 0.05),whichwere up-regulated
in follicles3mm(Fig. 4, C–E). This trend remained pres-
ent in nonestrogenic (P  0.078, P  0.085, and P 
0.084, respectively) and estrogenic (P  0.05, P  0.05,
and P  0.076; Fig. 4, C–E, respectively) follicles.
Although it initially appeared that thecal cell androgen
receptor (AR) gene expression was not affected by prenatal
androgenization (Fig. 4F), group separation revealed that
follicles thatwerenotproducingestrogenshad
up-regulated AR compared with controls,
whereas estrogen-producing follicles did not
(Fig. 4F). There was no effect of prenatal an-
drogenization on thecal cell receptivity to es-
trogens (ER; Fig. 4G). Similarly, this treat-
mentdidnotprogramchanges in thecal INHA
(Fig. 4H), INHBA (Fig. 4I), or INHBB (Fig.
4J) expression. Finally, the thecal cell expres-
sionof receptors for insulin (INSR; Fig. 4K)or
IGF-I (IGFR1; Fig. 4L) were not significantly
altered by prenatal androgenization. These
gene expression findings demonstrate up-reg-
ulation of thecal cellular steroidogenic ma-
chinery in TP-exposed animals that is associ-
ated with augmented steroid production in
these ovaries.
Discussion
Midgestation androgenization from d 62 to
d 102 of gestation does not lead to a poly-
cystic ovarian morphology in young adult
ewes. Other studies, albeit in the Poll Dorset
breed of sheep, have shown that polycystic
ovaries are present in 5-wk-old lambs as a
consequence of earlier and prolonged expo-
sure to TP from d 30 to d 90 (16). In PCOS,
the stockpiling of primary follicles has been
described, in which a greater number of
growing follicles are observed through developmental
stages (37). A reciprocal decrease in primordial follicle
number and increase in primary and antral follicles is re-
ported in women with PCOS (38). In the d 30–90 prena-
tally androgenized sheep, although there is no effect by
fetal d 90 (39), there is a decrease in ovarian reserve ob-
served in the fetal d 140ovary (40) andalso in the 8-month
ewe, although not in the 20-month ewe (41). In the sheep
PCOSmodel, follicular recruitment to growing follicles is
enhanced in addition to increased follicular persistence
(42, 43), which could contribute to an overall polycystic
morphology. Studies have also revealed, through treat-
ment of pregnant ewes with the nonaromatizable an-
drogen, dihydrotestosterone, that the dysregulated re-
cruitment of follicles is an androgenic effect, whereas
enhanced follicular persistence is likely a consequence
of estrogenic programming (39, 43).
In the current study, ovarian reserve is not affectedat11
months by prenatal TP exposure in the Scottish Greyface
ewe, in agreement with previous findings that germ cell
number is not altered in the d 90 fetal ovary in response to
FIG. 3. Androstenedione concentrations were measured in vivo in follicular fluid (A)
and in vitro in culture media before and after thecal stimulation with LH (B–D). In vitro
data are grouped by follicle size (B) and are compared using an ANOVA followed by a
Bonferroni pair-wise post hoc test (indicated by asterisks), and overall ANOVA outcomes
for the effect of increasing follicle diameter on androstenedione production in the TP-
exposed cohorts before () and after () LH were P  0.001. Additionally, in vitro data
are grouped by response to LH and analyzed using the paired t test (C) or by
prenatal treatment (D) and are analyzed using the unpaired t test. Data are divided
into follicle diameter classifications of sizes of 3 mm, 3–4 mm, and 4 mm.
Values are mean  SEM and P  0.05 was considered significant.
*, P  0.05; **, P  0.01.
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maternal TP administration from d 60–90 (36). Midges-
tation androgenization also did not result in an increased
number of primary, preantral or antral follicles at 11
months; however, the estrogenic status measured for in-
dividual follicles in the contralateral ovary revealed a sta-
tistically significant increase in the proportion of healthy
estrogen producing follicles compared with the control
cohort. This may be indicative of enhanced follicular per-
sistence in these animals that is not yet reflected by follicle
number. Differential findings between this study and oth-
FIG. 4. Thecal gene expression was measured in vivo by qRT-PCR using RNA extracted from individual follicles 3 mm in diameter (all; C  12,
TP  12). Data are further separated into follicles that were nonestrogenic (NE; C  7, TP  3) or estrogenic (E; C  5, TP  9). Genes assessed
were steroidal acute regulatory protein (StAR) (A), CYP11A (B), HSD3B1 (C), CYP17 (D), LHR (E), AR (F), estrogen receptor (ER) (G), INHA (H),
INHBA (I), INHBB (J), insulin receptor (INSR) (K), and IGF-I receptor (IGF1R) (L). Mean data  SEM are presented and an unpaired t test was
performed where *, P  0.05 and **, P  0.01.
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ers may be a consequence of breed as well as alternative
treatment periods, in which earlier exposure to androgens
over the period of sexual differentiation leads to an overall
more severe masculinized phenotype (21, 22). Since the
androgenic programming effects of TP have been demon-
strated to be important in the sheep for the programming
of increased follicular recruitment (39, 43), it is possible
that the shorter period of TP exposure in our study does
not induce such changes. Similarly to ovarianmorphology
and follicle number, animals exposed to androgens from
d 62 to d 102 did not exhibit peripheral hyperandrogen-
emia, had normal LH to FSH ratios as well as hypotha-
lamic pituitary ovarian function, and were fundamentally
not displaying the phenotypic criteria for diagnosis of
PCOS.
We therefore hypothesized that, before marked alter-
ation in ovarian morphology and the endocrine milieu, it
would be possible to detect intrinsic ovarian alterations
that may not be a consequence of the adult environment.
An assessment of thecal cell steroidogenic function was
subsequently carried out. Thecal cell secretion of andro-
stenedionewas determined in vivo bymeasurement in fol-
licular fluid. In the largest antral follicles (4 mm), there
was a trend for increased androstenedione secretion by
ovarian follicles of prenatally androgenized animals. An-
drostenedione concentrations in follicular fluid were still
raised in this cohort, despite an increase in the number of
follicles thatwere producing large amounts of estradiol. In
fact, when follicles were compared by estrogenic status,
the trend for increased androstenedione secretionwas still
present comparedwith controls, although sample sizewas
too small to reach robust conclusions. It seems, however,
that the rate of aromatization to estradiol by the granuolsa
cell is not responsible for the differences in the local con-
centration of androstenedione. These in vivo data repre-
sent a potential source of hormone dysregulation that
could contribute to the development of a systemic hy-
perandrogenic phenotype.
In PCOS, LH concentration, pulse frequency, and peak
amplitude are elevated (44). There is a positive association
between LH and peripheral androgen levels (45), and LH
stimulates excessive ovarian androgen production by
PCOS thecal cells in vitro (3). In the sheep PCOS model,
androgenization from fetal d 30 to d 90 leads to a per-
turbed gonadotropin milieu that is characterized by LH
hypersecretion and LH pulses that are increased in ampli-
tude and frequency (23, 46, 47). In the first breeding sea-
son, we did not observe disrupted LH concentrations or
altered pulse dynamics during the estrus phase in sheep
that were androgenized from d 62 to d 102; however, it
should be noted that other midgestationmodels of andro-
genization in Suffolk sheep have reported subtle altera-
tions in LH frequency measured through more frequent
blood sampling than this study. Nevertheless, ovulation
was unaffected in these animals (23). Although the en-
docrine milieu of the animals in the current study ap-
peared normal, we hypothesized that in the presence of
an abnormal adult hormonal environment, the hy-
perandrogenic phenotypeobserved in thecal cells,wouldbe
augmented.
In culture, androstenedione secretion was significantly
increased with increasing follicle size in follicles from TP-
exposed animals before and even more so after treatment
with LH, in comparison with controls. In addition, the
thecal cell response to LHwasmuch greater for prenatally
androgenized animals, particularly in the follicles4mm.
Inparallelwith the in vivodata, androstenedione secretion
was nonsignificantly increased in the TP group, compared
with controls, under basal culture conditions. However,
upon LH treatment of thecal cells, the increase in andro-
stenedione concentration in culture media was more ex-
aggerated and was 3-fold  in controls. These findings
demonstrate that in the prenatally androgenized ewe, not
only do follicular thecal cells have an increased propensity
to secrete androgens in vivo, but also an altered hormonal
environment simulated in this study by the addition of
exogenous LHcould contribute substantially to an overall
ovarian hyperandrogenic phenotype. These data are in
agreement with the findings of excessive basal and LH-
stimulated androgen production by human PCOS thecal
cells (3). The reduction in androstenedione secretion from
follicles3mm in diameter is also of interest. It is difficult
to reconcile but, combined with the subtle morphological
changes seen by immunohistochemistry, may suggest fur-
ther evidence for aberrant follicular function in thismodel.
To investigate the intrinsic properties that might war-
rant increased ovine thecal androgen production, in vivo
gene expression analyses were conducted in cells collected
from the noncultured portion of the thecal shell. Studies
assessing the factors that might lead to increased steroid
production in human PCOS thecal cells identified altera-
tions in gene expression related to the steroidogenic bio-
synthesis pathway, including the up-regulation of StAR
(13), CYP11A, and CYP17 (13, 14) as well as increased
enzymatic activity of 17-OH, 3-HSD, and 17-HSD
(14). Assessment of our prenatally androgenized ovine
model also identified the up-regulation of many genes in-
volved in steroid biosynthesis including StAR, CYP11A,
HSD3B1 and CYP17. Furthermore, thecal LHR gene ex-
pression was increased in these animals, a finding that has
also been reported in human thecal cells from PCOS pa-
tients (13).Granulosa cellswere also collected at this time;
however, yields from individual follicles were found to be
too low to obtain satisfactory RNA concentrations and
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purities. Study of the FSH receptor (FSHR) in granulosa
cells of individual follicles and the above steroidogenic
genes as well as CYP19 (aromatase) would have been of
interest and may have provided explanation for the in-
creased proportions of estrogenic follicles present in the
androgenized cohort. Nevertheless, these data provide
further evidence for functional ovarian programming by
prenatal androgens in the sheep, and like in human studies
of PCOS thecal cells, there may be an increased drive of
cholesterol through the steroidogenic pathway and an en-
hanced sensitivity to LHdue to an increase in thecalLHR,
present in this ovine model. Given that the thecal cell ef-
fects of prenatal androgenization include global up-regu-
lation of steroidogenic genes as well as hypersecretion of
androgensboth in vivoand in vitro, it is perhaps surprising
that there is no measurable alteration in peripheral an-
drogen concentrations. We suspect that the capacity for
aromatization canmaintain the normal circulating andro-
gen concentrations at this stage.
Since the activins and inhibins have opposite effects on
thecal androstenedione production, suppressing and pro-
moting secretion, respectively (48–50), we hypothesized
that local signaling by these factors could contribute to the
ovarian phenotype. Prenatal androgenization did not,
however, alter the expression of the inhibin subunits in
the thecal cells of these animals. Unfortunately, due to the
inability to investigate inhibin subunit expression in the
granulosa cells, which are the predominant site of ovarian
activin and inhibin production, assessment was limited to
the thecal cells. Other investigators have studied the ex-
pression of the activin and inhibin subunits in the d 30–90
prenatally androgenized 5-wk-old lamb and, through in
situ hybridization, have found that INHBBmRNAwas in
fact down-regulated in whole follicles (16).
The stimulatory effect of insulin and IGF-I on ovarian
androgen production has been documented (51–54), and
therefore, we investigated whether receptor gene expres-
sion for these ligands, INSR or IGF1R, were affected by
prenatal androgen exposure. These geneswere not altered
by increased exposure to prenatal androgens. It is, how-
ever, interesting to note that in this same ovine model of
midgestation androgenization, there is a slightly exagger-
ated insulin response to glucose load, although basal in-
sulin concentration and glucose clearance are not changed
at this stage. Also, there is increased hepatic IGF1mRNA
expression in these young adult sheep (55). These findings
might indicate early physiological perturbations in the en-
vironment that, as they develop, could influence adult
ovarian function. Although we show that altered theca
steroidogenesis is the predominant abnormality in these
young sheep, it remains impossible to fully temporarily
separate theca cell alterations and minor metabolic
changes.
It is clear that there are intrinsic ovarian abnormalities
that are programmed by prenatal exposure to androgens
that are not associated with an abnormal PCO-like mor-
phology or an altered steroid or gonadotropin environ-
ment. This suggests the presence of a pre-PCOSphenotype
that is observable in this ovine model of PCOS, in which
midgestation androgens program more subtle reproduc-
tive anomalies than is reported in animals exposed to an-
drogens for a prolonged gestational period as well as in
different breeds. We have previously shown in this model
that just 10 d of androgen exposure, commencing at d 60,
is sufficient to alter protein expression in the d 70 fetal
ovary (36). The AR is strongly expressed in the interstitial
somatic streams of the d 70 fetal ovary, and therefore,
androgens can directly act on the ovary during this time.
Prenatal TP treatment results in a trend for increased AR
in the d 70 ovary and presents a mechanism for the pro-
gramming of ovarian somatic cells that may include pre-
granulosa and/or thecal progenitor cells (36). Further-
more, this treatment programs an up-regulation of
regulatory proteins involved in proliferation and differ-
entiation known as the inhibitors of differentiation and
also down-regulates steroidogenic gene expression in the
midgestation ovary (36). Interestingly, contemporary tes-
tosterone exposure in utero reduced the expression of ste-
roidogenic enzymes and LH receptor in the d 90 fetal
ovary (36), whereas previous prenatal exposure increased
theca steroidogenic capacity as young adults. The effects
in the fetus may be secondary to the suppressed gonado-
tropins (Hogg, K. and W.C. Duncan, unpublished data),
whicharenormal in theadult, or another indicatorof early
disordered ovarian steroidogenic capacity. These changes
in the fetal ovary as a consequence of exposure to andro-
gens may be linked to the intrinsic alterations observed in
the adult ovary.
Further studies will be required to dissect the longitu-
dinal changes to ovarian function as a consequence of
these early changes. However, this study has for the first
time characterized thecal cell androgen production and
steroidogenic gene expression in a prenatal androgeniza-
tion model. Midgestation androgenization programs en-
hanced thecal cell androgen production in the adult sheep
ovary,which is likelydrivenby theuniversal up-regulation
of genes involved in steroid biosynthesis. Further augmen-
tation of these pathways may occur through ovarian ex-
posure to an altered adult environment including elevated
LH and insulin levels, which are common features of
PCOS.
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